11:33 AM EST, 12/12/2024 (MT Newswires) -- Aptose Biosciences ( APTO ) on Thursday announced the publication of preclinical data for its lead hematology compound tuspetinib (TUS) in Cancer Research Communications, a journal of the American Association for Cancer Research (AACR).

The paper is the first preclinical profiling of tuspetinib, a once daily, oral kinase inhibitor currently in clinical development for treatment of acute myeloid leukemia (AML).

Aptose is now enrolling newly diagnosed AML patients in a Phase 1/2 clinical study to receive the tuspetinib with two other medications. Clinical studies in patients with relapsed or refractory AML receiving TUS single agent or with one other medication have been completed.

"The non-clinical findings presented in the publication suggest that TUS will demonstrate favorable safety and a breadth of antileukemic activity across AML patient populations with a diversity of adverse mutations, and the initial clinical data is bearing that out," said CEO William Rice.

The company's shares were last seen up $0.01 to $0.27 on the Toronto Stock Exchange.

Price: 0.27, Change: +0.01, Percent Change: +3.85